901259-15-2
Chemical Structure
CBS1194
- CAS No.: 901259-15-2
- Formula:C22H19BrN4O2
- Molecular Weight:451.32
IUPAC Name: 2-(3-bromophenyl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5,7-dimethylimidazo[1,2-a]pyrimidin-3-amine
InChIKey: KCLAAMVCRHVUGX-UHFFFAOYSA-N
SMILES: BrC1=CC=CC(=C1)C=2N=C3N=C(C=C(N3C2NC4=CC=C5OCCOC5=C4)C)C
Biological Activity: CBS1194 is a selective group 2 influenza virus inhibitor. CBS1194 binds to the pocket region adjacent to the HA fusion peptide, generates steric hindrance, and blocks the low pH-induced HA conformational rearrangement required for membrane fusion. CBS1194 exerts inhibitory activity in the early stage of viral infection and can inhibit HA-mediated hemolysis. CBS1194 serves as a lead compound for the development of improved influenza virus entry inhibitors. CBS1194 is applicable to studies related to influenza virus infection[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CBS1194 | CBS1194 is a selective group 2 influenza virus inhibitor. CBS1194 binds to the pocket region adjacent to the HA fusion peptide, generates steric hindrance, and blocks the low pH-induced HA conformational rearrangement required for membrane fusion. CBS1194 exerts inhibitory activity in the early stage of viral infection and can inhibit HA-mediated hemolysis. CBS1194 serves as a lead compound for the development of improved influenza virus entry inhibitors. CBS1194 is applicable to studies related to influenza virus infection. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Lin X, et al. Optimization and applications of an in vivo bioluminescence imaging model of influenza A virus infections. Virologica Sinica. 2023 Aug;38(4):631-634.
- [2]. Du R, et al. Identification of a novel inhibitor targeting influenza A virus group 2 hemagglutinins. Antiviral research. 2021 Feb;186:105013.
- [3]. Chen Z, et al. Small Molecule Inhibitors of Influenza Virus Entry. Pharmaceuticals (Basel, Switzerland). 2021 Jun 18;14(6):587. [Content Brief]
- [4]. Xu Y, et al. Mechanistic insights into the small-molecule inhibition of influenza A virus entry. Proceedings of the National Academy of Sciences of the United States of America. 2025 Aug 19;122(33):e2503899122.
Keywords
